Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071024 | 0.84 | CYP8B1 (0.45) | CYP8B1KCNH2 | |
| SCHEMBL4062836 | 0.81 | KCNH2 (0.39) | CYP8B1KCNH2SLC2A1ADORA2AADORA1 | |
| SCHEMBL3167861 | 0.80 | CYP8B1 (0.49) | CYP8B1KCNH2SLC2A1 | |
| SCHEMBL3168285 | 0.76 | CYP8B1 (0.49) | CYP8B1KCNH2SLC2A1 | |
| SCHEMBL13527137 | 0.75 | CYP8B1 (0.47) | CYP8B1KCNH2SLC2A1 | |
| SCHEMBL1222970 | 0.75 | CYP8B1 (0.38) | CYP8B1KCNH2 | |
| SCHEMBL1222972 | 0.75 | CYP8B1 (0.38) | CYP8B1KCNH2 | |
| SCHEMBL5752149 | 0.73 | CYP8B1 (0.47) | CYP8B1KCNH2SLC2A1 | |
| SCHEMBL4064056 | 0.73 | KCNH2 (0.40) | KCNH2 | |
| SCHEMBL4069637 | 0.71 | SIRT2 (0.47) | CYP8B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| EP-1605938-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060189601-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| EP-1605938-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004087145-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189601-A1 | Antibacterial agents | NQO2, NRDC, IFNG | CYP8B1 1990/4885KCNH2 3365/4885PRKCA 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.